LAB Q3 2019 Earnings — Standard BioTools Inc. Revenue & Financial Results | Market Cap Arena

LABStandard BioTools Inc.

$370M

Q3 2019 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$26M-8.5% YoY

Gross Profit

$14M53.0% margin

Operating Income

-$14M-52.1% margin

Net Income

-$13M-48.6% margin

EPS (Diluted)

$-0.19

QoQ Revenue Growth

-6.0%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$6M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$269M

Total Liabilities

$107M

Stockholders' Equity

$163M

Cash & Equivalents

$26M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$26M	$29M	-8.5%
Gross Profit	$14M	$16M	-11.3%
Operating Income	-$14M	-$12M	-18.8%
Net Income	-$13M	-$15M	+12.6%

Revenue Segments

Product

$21M44%

Consumables

$12M24%

Instruments

$9M19%

Service

$6M12%

Grant Revenue

$200,0000%

Geographic Segments

Americas

$11M42%

Europe

$9M34%

Asia Pacific

$6M24%